Expression pattern and prognostic significance of myosin light chain 9 (MYL9): A novel biomarker in glioblastoma

Kruthika, BS and Sugur, H and Nandaki, K and Arimappamagan, A and Paturu, K and Santosh, V (2019) Expression pattern and prognostic significance of myosin light chain 9 (MYL9): A novel biomarker in glioblastoma. In: Journal of Clinical Pathology, 72 (10). pp. 677-681.

PDF jou_cli_pat_72-10_677-681_2019.pdf - Published Version Restricted to Registered users only Download (755kB) | Request a copy

Abstract

Aims Tumour recurrence is inevitable in glioblastoma (GBM) and mostly noted in the peritumoural brain zone (PT). In our previous microarray-based study, we identified Myosin Light Chain 9 (MYL9) as a highly expressed gene in the PT of GBM. Therefore, we aimed to study the expression pattern and clinical significance of MYL9 in GBM. Methods Patient samples included three retrospective cohorts: 25 GBM cases with differential biopsies of tumour core and PT, 62 retrospective cases of newly diagnosed GBM with survival information and 20 paired samples (newly diagnosed and recurrent GBM). All tumour tissues, archived as formalin fixed paraffin embedded blocks were retrieved and immunohistochemistry for MYL9 and IDH1 R132H was performed. MYL9 expression was correlated with patient prognosis in our cohort and in The Cancer Genome Atlas (TCGA) and Rembrandt cohorts. It was further evaluated in the 20 paired samples of GBM. Results MYL9 showed a cytoplasmic membranous staining of tumour cells. The staining pattern was variable and patchy within tumours. Higher MYL9 expression was associated with poor overall and progression-free survival in our and in TCGA and Rembrandt cohorts. The expression of MYL9 was higher in IDH1 R132H immunonegative cases. Conclusions We show MYL9 as a novel biomarker, variably expressed in GBM. The association of high MYL9 expression with poor prognosis in newly diagnosed GBM patients and increased expression in recurrent GBM is indicative of its role in conferring tumour aggressiveness. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Item Type:	Journal Article
Publication:	Journal of Clinical Pathology
Publisher:	BMJ Publishing Group
Additional Information:	The copyright for this article belongs to BMJ Publishing Group.
Keywords:	myosin light chain; myosin light chain 9; temozolomide; tumor marker; unclassified drug; MYL9 protein, human; myosin light chain; tumor marker, adult; aged; Article; cancer prognosis; cancer recurrence; cancer survival; cohort analysis; controlled study; female; glioblastoma; human; human tissue; immunohistochemistry; major clinical study; male; multiple cycle treatment; overall survival; priority journal; progression free survival; protein expression; retrospective study; survival analysis; survival rate; tumor biopsy; tumor recurrence; brain tumor; glioblastoma; metabolism; middle aged; pathology; prognosis; young adult, Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Myosin Light Chains; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Young Adult
Department/Centre:	Division of Biological Sciences > Molecular Reproduction, Development & Genetics
Date Deposited:	05 Jan 2023 09:44
Last Modified:	05 Jan 2023 09:44
URI:	https://eprints.iisc.ac.in/id/eprint/78787

Actions (login required)

View Item